Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995144 · ClinicalTrials.gov registry record · Phase 4
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
A Phase 4 study of Heart Failure and Edema, sponsored by Sarfez Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06995144: Completed Phase 4 study of Heart Failure and Edema, sponsored by Sarfez Pharmaceuticals.
NCT06995144 is a Phase 4 study of Heart Failure and Edema that has completed, run by Sarfez Pharmaceuticals. The registered enrollment target is 20 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06995144, a Phase 4 study of Heart Failure and Edema, has completed, sponsored by Sarfez Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Primary Outcome
Urinary sodium excretion (mmol) measured after dosing: 4-8 hours (post-lunch period)
Conditions Studied
Interventions
- DRUG Extended Release Torsemide Tablets
- DRUG Immedate Release Torsemide Tablets
Study Locations (1)
Florida
- Future Life Clinical Trials - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 4 |
What the finished NCT06995144 record still lists
NCT06995144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Extended Release Torsemide Tablets is the first listed.
NCT06995144 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06995144 about?
NCT06995144 is a clinical study titled "Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure". The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who a...
What is the current status of trial NCT06995144?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-05-28. Estimated completion is 2025-12-30.
What conditions does trial NCT06995144 study?
This clinical trial studies the following conditions: Heart Failure, Edema, Fluid Overload, Pulmonary Congestion.
What interventions are being tested in trial NCT06995144?
The interventions under investigation include: Extended Release Torsemide Tablets (DRUG), Immedate Release Torsemide Tablets (DRUG).
Who is sponsoring clinical trial NCT06995144?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995144 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06995144's enrollment target sits among peer trials
20 350th of 397 higher than 37 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI